Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1957 1
1958 1
1960 1
1961 1
1962 1
1965 1
1967 1
1968 2
1969 1
1971 1
1972 1
1975 1
1977 1
1983 1
1986 2
1988 2
1990 1
1999 1
2000 2
2001 1
2002 2
2003 4
2004 4
2005 8
2006 7
2007 20
2008 15
2009 9
2010 16
2011 17
2012 11
2013 16
2014 18
2015 18
2016 18
2017 13
2018 17
2019 12
2020 20
2021 15
2022 18
2023 14
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

281 results

Results by year

Filters applied: . Clear all
Page 1
Anterior open bite - diagnostics and therapy.
Michl P, Broniš T, Jurásková Sedlatá E, Heinz P, Pink R, Šebek J, Mottl R, Dvořák Z, Tvrdý P. Michl P, et al. Among authors: dvorak z. Acta Chir Plast. 2021 Winter;63(4):181-184. doi: 10.48095/ccachp2021181. Acta Chir Plast. 2021. PMID: 35042361 Review. English.
Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases.
Michaudel C, Danne C, Agus A, Magniez A, Aucouturier A, Spatz M, Lefevre A, Kirchgesner J, Rolhion N, Wang Y, Lavelle A, Galbert C, Da Costa G, Poirier M, Lapière A, Planchais J, Nádvorník P, Illes P, Oeuvray C, Creusot L, Michel ML, Benech N, Bourrier A, Nion-Larmurier I, Landman C, Richard ML, Emond P, Seksik P, Beaugerie L, Arguello RR, Moulin D, Mani S, Dvorák Z, Bermúdez-Humarán LG, Langella P, Sokol H. Michaudel C, et al. Among authors: dvorak z. Gut. 2023 Jul;72(7):1296-1307. doi: 10.1136/gutjnl-2022-327337. Epub 2022 Oct 21. Gut. 2023. PMID: 36270778 Free PMC article.
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S; FUTURE 2 Study Group. McInnes IB, et al. Lancet. 2015 Sep 19;386(9999):1137-46. doi: 10.1016/S0140-6736(15)61134-5. Epub 2015 Jun 28. Lancet. 2015. PMID: 26135703 Free article. Clinical Trial.
Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, Forejtova S, Zwillich SH, Gruben D, Koncz T, Wallenstein GV, Krishnaswami S, Bradley JD, Wilkinson B; ORAL Standard Investigators. van Vollenhoven RF, et al. N Engl J Med. 2012 Aug 9;367(6):508-19. doi: 10.1056/NEJMoa1112072. N Engl J Med. 2012. PMID: 22873531 Free article. Clinical Trial.
Single-conflict colouring.
Dvořák Z, Esperet L, Kang RJ, Ozeki K. Dvořák Z, et al. J Graph Theory. 2021 May;97(1):148-160. doi: 10.1002/jgt.22646. Epub 2020 Nov 4. J Graph Theory. 2021. PMID: 33888935 Free PMC article.
Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.
van der Heijde D, Strand V, Tanaka Y, Keystone E, Kremer J, Zerbini CAF, Cardiel MH, Cohen S, Nash P, Song YW, Tegzová D, Gruben D, Wallenstein G, Connell CA, Fleischmann R; ORAL Scan Investigators. van der Heijde D, et al. Arthritis Rheumatol. 2019 Jun;71(6):878-891. doi: 10.1002/art.40803. Epub 2019 Apr 24. Arthritis Rheumatol. 2019. PMID: 30666826 Free PMC article. Clinical Trial.
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.
van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, Van den Bosch F, Sieper J, Tomita T, Landewé R, Zhao F, Krishnan E, Adams DH, Pangallo B, Carlier H; COAST-V study group. van der Heijde D, et al. Lancet. 2018 Dec 8;392(10163):2441-2451. doi: 10.1016/S0140-6736(18)31946-9. Epub 2018 Oct 22. Lancet. 2018. PMID: 30360964 Clinical Trial.
Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis.
Smolen JS, Feist E, Fatenejad S, Grishin SA, Korneva EV, Nasonov EL, Samsonov MY, Fleischmann RM; CREDO2 Group. Smolen JS, et al. N Engl J Med. 2022 Aug 25;387(8):715-726. doi: 10.1056/NEJMoa2201302. N Engl J Med. 2022. PMID: 36001712 Clinical Trial.
281 results